Comments
Alembic Pharmaceuticals Limited, on Friday, posted over three-fold jump in standalone net profit for the quarter ended March 31, 2023, at ₹131 crore, up from ₹42 crore in the same quarter last year, supported by reduction in total expenses.
Standalone revenues from operations stood at ₹1,307 crore ( ₹1,318 crore) for the quarter. The total expenses for the quarter stood at ₹1,225 crore, down by 4.2 per cent from ₹1,280 crore in the corresponding quarter last year. For the full year, however, the profits came under pressure on overall higher costs. Standalone net profit for the year stood at ₹347 crore, down 36 per cent from ₹544 crore in the previous year. Annual revenues for the fiscal stood at ₹5,149 crore, up from ₹5,035 crore in the previous year. Total expenses increased by 9 per cent to ₹4,807 crore ( ₹4,429 crore).
The Board of Directors met on Friday and recommended a dividend of ₹8 (or 400 per cent) per equity share having face value of ₹2 each. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited, said: “The US business continues to remain challenging, however, the company witnessed topline growth across all other verticals. In particular, the API business outperformed with a 41 per cent growth and Ex-US generics with 33 per cent growth during the quarter. We have started commercialisation of products from our injectable and oncology facilities. India-branded business continues to outperform the market, especially on focussed products / therapeutic segments.”
Stock Call. How R&D spends make Alembic Pharmaceuticals a good buy
On the operational front, company’s Active Pharmaceutical Ingredients (API) business grew 41 per cent at ₹313 crore during the quarter. Barring US, its ex-US and India formulations businesses grew by 33 per cent and 9 per cent, respectively, during the quarter. Among other growth drivers, were specialty segments that grew 13 per cent, including Gynecology, Anti-Diabetic, Ophthalmology & Ortho. Company’s animal health business grew 15 per cent over previous year Q4.
On a consolidated basis, company’s net profits for March quarter stood at ₹153 crore (versus ₹22 crore) on revenues of ₹ 1,406 crore ( ₹1,416 crore). Total expenses fell by nearly ₹100 crore to ₹1,283 crore ( ₹1,385 crore). For the fiscal 2022-23, company’s consolidated net profit stood at ₹342 crore ( ₹521 crore), on revenues of ₹5,653 crore ( ₹5,306 crore). Total consolidated expenses for the year increased to ₹5,270 crore ( ₹4,736 crore).
Alembic Pharmaceuticals shares ended lower by 0.98 per cent at ₹554.40 on the BSE on Friday.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.